Organotypic 3D Assay Platforms In Development

“The development of physiologically relevant models should recognise that organs and tissues function in a 3D environment… and in the final analysis, the organ itself is the unit of function.”

Schmeichel & Bissell, 2003

Advantages of the OrganDOT™ System

  • 3D microtissues recapitulate original tissue architecture and functionality
  • Robust function, longevity.
  • Compatible with multiple endpoint assays such as: mediator release, cell viability/proliferation/apoptosis, ICC & qRT-PCR
  • Simultaneous testing of multiple treatments and schedules delivers comprehensive compound profiles within a shorter time period
  • Established isletOrganDOT™
  • Potential to be applied to different cell type systems
  • Liver (hepatocyte, stellate and Kupffer cell co-culture)
  • Lung (tumor cells + CAFs co-culture)


Liver Fibrosis

Asterand Bioscience received funding in September 2014 from the UK Technology Strategy Board (Innovate UK) to lead the development of a 3D multicellular liver fibrosis model.  We are collaborating with the University of Manchester for the parallel evaluation of a matrix-free (OrganDOT™) and matrix-based (RAFT™) platform.


Asterand Bioscience is developing 3D human primary multicellular oncology models using the OrganDOT™ platform.  Initial development work has been completed using a lung cancer cell line. Asterand Bioscience has also used soft gel 3D culture approaches for the co-culture of primary tumor epithelial cells + cancer associated fibroblasts (HuCAFs).

lung_cancer_web_imageHuman lung cancer cell line forms 3D aggregates in the OrganDOT™ platform. These cells express the epithelial marker cytokeratin and remain viable over long-term culture.
Stauro_Web_ImageEffects of the apoptosis inducer staurosporine on human lung cancer cell line in OrganDOT™ culture. Staurosporine induces caspase activity and causes loss of cell viability in 3D cultures of human tumour cells.


For further information, contact us at